Home AboutCriteriaPortfolioTeamContact
HomeAffiliatesNewsSite Map
 
   

Hunt BioVentures
Hunt Ventures
Hunt Energy Enterprises
Hunt Growth Capital
Hunt Private Equity Group
Hunt Special Situations Group

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acorda (NASDAQ: ACOR)

Acorda develops therapeutic products for spinal cord injury and other central nervous system disorders.
(IPO February 2006)
www.acorda.com

 

 
 

 

Anesiva (NASDAQ: ANSV)

Anesiva develops innovative drugs for the treatment of acute and chronic pain.
(Originally AlgoRx, merger w/ Corgentech in December 2005)
www.anesiva.com

 

 
 

 

Athenix

Athenix develops and commercializes high-value genetic traits from microbes for use in agricultural products.
www.athenixcorp.com

 

 
 

 

Avalon (NASDAQ: AVRX)

Avalon discovers and develops novel drugs for various cancers.
www.avalonrx.com

 

 
   

BioMs (TSX: MS)

BioMs develops unique biologics for autoimmune diseases with a special emphasis on multiple sclerosis.
www.biomsmedical.com

 

 
 

 

 

IntelliDx

IntelliDx is a medical technology company that is developing an automated, bedside blood analyzer for use in the critical care areas of hospitals.

http://www.intellidx.com/

 
   

MacroGenics

MacroGenics is focused on the development of improved immunotherapeutic products and the identification of new targets for the treatment of cancer and inflammatory diseases.
www.macrogenics.com

 

 
   

Morphotek

Morphotek develops therapeutic monoclonal antibodies for the treatment of cancer, inflammatory and infectious diseases.
(Acquired by Eisai Corp. of Japan in April 2007)
www.morphotek.com

 

 
   

Myogen (NASDAQ: MYOG)

Myogen is engaged in the discovery and development of drugs for the treatment of heart failure and related cardiovascular conditions.
(Acquired by Gilead Sciences (NASDQ: GILD)
www.myogen.com

 

 
   

Novelos (OTC BB: NVLT)

Novelos develops oxidized glutathione-based drugs for the treatment of cancer and hepatitis.
www.novelos.com

 

 
   

Peptimmune

Peptimmune develops drugs for the treatment of various autoimmune diseases.
www.peptimmune.com

 

 
   

Salmedix

Salmedix develops oncology drugs with an initial emphasis on hematologic cancers.
(Acquired by Cephalon (NASDQ: CEPH)
www.cephalon.com

 

 
   

Sirtris (NASDAQ: SIRT)

Sirtris develops novel treatments for metabolic disease with a focus on sirtuin enzymology.
(Acquired by GlaxoSmithKline in June 2008.)
www.sirtrispharma.com

 

 
 

©2006 Hunt BioVentures All Rights Reserved
| Legal Notice | About | Criteria | Portfolio | Team | Contact | Affiliates | News | Site Map |